U.S. markets open in 3 hours 52 minutes
  • S&P Futures

    4,470.50
    -3.75 (-0.08%)
     
  • Dow Futures

    34,742.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    15,499.75
    -18.00 (-0.12%)
     
  • Russell 2000 Futures

    2,231.00
    -2.20 (-0.10%)
     
  • Crude Oil

    72.01
    -0.60 (-0.83%)
     
  • Gold

    1,766.00
    +9.30 (+0.53%)
     
  • Silver

    23.09
    +0.30 (+1.30%)
     
  • EUR/USD

    1.1784
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.80
    +0.62 (+3.41%)
     
  • GBP/USD

    1.3795
    -0.0002 (-0.01%)
     
  • USD/JPY

    109.9700
    +0.2520 (+0.23%)
     
  • BTC-USD

    47,819.71
    -376.89 (-0.78%)
     
  • CMC Crypto 200

    1,220.52
    -12.77 (-1.04%)
     
  • FTSE 100

    7,038.55
    +11.07 (+0.16%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

StemCells announce first transplant in phase 1,2 trial in AMD

StemCells announced dosing of the first high-dose patient in the company's Phase 1,2 clinical trial in dry age-related macular degeneration.The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with 1M HuCNS-SC cells. The first four patients each received a dose of 200K cells. An independent Data Safety Monitoring Committee conducted a review of the trial data to date, and found no safety issues to preclude the trial from proceeding to the high dose.